Literature DB >> 11035577

Estrogen and progesterone receptors in non-small cell lung cancer in 248 consecutive patients who underwent surgical resection.

L Di Nunno1, L G Larsson, J J Rinehart, R S Beissner.   

Abstract

CONTEXT: Different authors have reported estrogen receptor (ER) expression between 0% and 96.8% and progesterone receptor (PR) expression between 21.8% and 34.7%.
OBJECTIVE: To examine the discrepancies in the literature regarding the expression of ERs and PRs in non-small cell lung cancer.
DESIGN: Retrospective analysis.
SETTING: A referral tertiary care center. PATIENTS: We reviewed 248 consecutive cases of stage I and II non-small cell lung cancers. METHODS AND
RESULTS: Sections of formalin-fixed and paraffin-embedded tumor tissue were stained with ER and PR monoclonal antibodies using the avidin-biotin complex detection system with antigen retrieval. Men represented 66.1% of the patients, and women represented 33.9%. Large cell (undifferentiated) carcinoma constituted 10.4% of the entire population; squamous cell carcinoma, 39.1%; adenocarcinoma, 33.0%; and bronchoalveolar carcinoma, 17.3%. Patients with stage I disease represented 77.0% of the population. In this patient population, we found no nuclear or cytoplasmic expression of either ERs or PRs (95% confidence interval, 0%-1.2%).
CONCLUSIONS: The absence of expression of ERs and PRs differs from previous articles, which use a variety of techniques, impairing a meaningful comparison of data. In addition, the presence of ER and PR expression in a lung carcinoma is supportive of a nonpulmonary primary tumor metastatic to the lung. The absence of their expression in non-small cell lung cancer does not support a role of these transcription factors in initiating and maintaining this neoplastic process.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11035577     DOI: 10.5858/2000-124-1467-EAPRIN

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  22 in total

1.  Targeting the estrogen pathway for the treatment and prevention of lung cancer.

Authors:  Timothy F Burns; Laura P Stabile
Journal:  Lung Cancer Manag       Date:  2014-02-01

2.  Serum estrogen and tumor-positive estrogen receptor-alpha are strong prognostic classifiers of non-small-cell lung cancer survival in both men and women.

Authors:  Susan E Olivo-Marston; Leah E Mechanic; Steen Mollerup; Elise D Bowman; Alan T Remaley; Michele R Forman; Vidar Skaug; Yun-Ling Zheng; Aage Haugen; Curtis C Harris
Journal:  Carcinogenesis       Date:  2010-08-20       Impact factor: 4.944

3.  Estrogen receptor expression in sporadic vestibular schwannomas.

Authors:  Carrie M Brown; Zana K Ahmad; Allen F Ryan; Joni K Doherty
Journal:  Otol Neurotol       Date:  2011-01       Impact factor: 2.311

Review 4.  Estrongenic steroid hormones in lung cancer.

Authors:  Jill M Siegfried; Laura P Stabile
Journal:  Semin Oncol       Date:  2013-12-12       Impact factor: 4.929

Review 5.  A potential role for estrogen in cigarette smoke-induced microRNA alterations and lung cancer.

Authors:  Amit Cohen; Mario Alberto Burgos-Aceves; Yoav Smith
Journal:  Transl Lung Cancer Res       Date:  2016-06

6.  Progesterone and estrogen receptor expression and activity in human non-small cell lung cancer.

Authors:  Diana C Marquez-Garban; Vei Mah; Mohammad Alavi; Erin L Maresh; Hsiao-Wang Chen; Lora Bagryanova; Steve Horvath; David Chia; Edward Garon; Lee Goodglick; Richard J Pietras
Journal:  Steroids       Date:  2011-05-08       Impact factor: 2.668

7.  Estrogen receptor expression and gene promoter methylation in non-small cell lung cancer - a short report.

Authors:  Xavier Tekpli; Vidar Skaug; Rita Bæra; David H Phillips; Aage Haugen; Steen Mollerup
Journal:  Cell Oncol (Dordr)       Date:  2016-08-29       Impact factor: 6.730

Review 8.  Estrogen receptors as the novel therapeutic biomarker in non-small cell lung cancer.

Authors:  Hideki Kawai
Journal:  World J Clin Oncol       Date:  2014-12-10

9.  Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation.

Authors:  Maria G Raso; Carmen Behrens; Matthew H Herynk; Suyu Liu; Ludmila Prudkin; Natalie C Ozburn; Denise M Woods; Ximing Tang; Reza J Mehran; Cesar Moran; J Jack Lee; Ignacio I Wistuba
Journal:  Clin Cancer Res       Date:  2009-08-25       Impact factor: 12.531

10.  Hormone replacement therapy and outcomes for women with non-small-cell lung cancer: can an association be confirmed?

Authors:  O Ayeni; A Robinson
Journal:  Curr Oncol       Date:  2009-05       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.